METHODS: We performed a comparative study in 50 adult Mexican patients with obesity treated with GS or BBR for 3 months. The baseline and final biochemical parameters, body composition, blood pressure, gene expression of Res, Ome, Vis, and Ap, and safety parameters were evaluated.
RESULTS: BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression and increased Ome, while GS decreased fasting glucose and Res gene expression (p < 0.05). A comparative analysis of the final measurements revealed a lower gene expression of Ap and Vis (p < 0.05) in patients treated with BBR than in those treated with GS. The most frequent adverse effects in both groups were gastrointestinal symptoms, which attenuated during the first month of treatment.
CONCLUSIONS: In patients with obesity, BBR has a better effect on body composition, blood pressure, and the gene expression of adipokines related to metabolic risk, while GS has a better effect on fasting glucose and adipokines related to insulin resistance, with minimal side effects.
方法:我们在50名墨西哥成年肥胖患者中进行了一项比较研究,患者接受GS或BBR治疗3个月。基线和最终生化参数,身体成分,血压,Res的基因表达,Ome,Vis,还有Ap,并对安全参数进行了评估。
结果:BBR显着降低(p<0.05)体重,血压和Vis和Ap基因表达以及Ome增加,而GS降低空腹血糖和Res基因表达(p<0.05)。最终测量结果的比较分析显示,与用GS治疗的患者相比,用BBR治疗的患者中Ap和Vis的基因表达较低(p<0.05)。两组中最常见的不良反应是胃肠道症状,在治疗的第一个月减弱。
结论:在肥胖患者中,BBR对身体成分有更好的影响,血压,以及与代谢风险相关的脂肪因子的基因表达,而GS对空腹血糖和与胰岛素抵抗相关的脂肪因子有更好的影响,副作用最小。